Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 5
2015 2
2016 1
2018 2
2019 4
2020 2
2021 10
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: takayanagi d. Lung Cancer. 2023 May;179:107183. doi: 10.1016/j.lungcan.2023.107183. Epub 2023 Mar 25. Lung Cancer. 2023. PMID: 37037178
Characteristics of anal canal squamous cell carcinoma as an HPV-associated cancer in Japan.
Yamada K, Shiraishi K, Takashima A, Takayanagi D, Saiki Y, Takano S, Tanaka M, Fukunaga M, Sugimoto K, Iwasaki Y, Nakamura Y, Kuwahara D, Tsuji Y, Takano M, Sugihara K, Ajioka Y. Yamada K, et al. Among authors: takayanagi d. Int J Clin Oncol. 2023 Aug;28(8):990-998. doi: 10.1007/s10147-023-02339-5. Epub 2023 Apr 28. Int J Clin Oncol. 2023. PMID: 37115427 Review.
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses.
Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Shiraishi K, et al. Among authors: takayanagi d. Cancer Commun (Lond). 2024 Feb;44(2):287-293. doi: 10.1002/cac2.12498. Epub 2023 Oct 26. Cancer Commun (Lond). 2024. PMID: 37882647 Free PMC article. No abstract available.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: takayanagi d. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: takayanagi d. Front Immunol. 2023 Sep 18;14:1260492. doi: 10.3389/fimmu.2023.1260492. eCollection 2023. Front Immunol. 2023. PMID: 37790929 Free PMC article.
NTRK fusion-positive colorectal cancer in Japanese population.
Yonemaru J, Hashimoto T, Takayanagi D, Naka T, Yatabe Y, Kanemitsu Y, Shiraishi K, Sekine S. Yonemaru J, et al. Among authors: takayanagi d. Pathol Int. 2021 May;71(5):355-359. doi: 10.1111/pin.13082. Epub 2021 Feb 25. Pathol Int. 2021. PMID: 33631044
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S. Hashimoto T, et al. Among authors: takayanagi d. Br J Cancer. 2022 Oct;127(6):1043-1050. doi: 10.1038/s41416-022-01880-w. Epub 2022 Jun 17. Br J Cancer. 2022. PMID: 35715628 Free PMC article.
36 results